Key Highlights

  • First-quarter fiscal 2027 Revenue fell 22% to $53.8 million.
  • Gross profit declined 39% to $18.8 million, and gross Margin narrowed to 35.0% from 44.5%.
  • Adjusted EBITDA was $5.3 million, down from $13.9 million, but up sequentially for a second quarter.
  • The company disputes the foreclosure of its Pro Farm Group business, and litigation is continuing.

Bioceres Crop Solutions Corp. (NASDAQ:BIOX), an agricultural biotechnology company with operations in Argentina, reported results for its fiscal first quarter of 2027, covering the period ended September 30, 2026. Revenue of $53.8 million was down 22% from a year earlier, while net loss from continuing operations widened to $10.8 million. The company's results reflect both a slower seasonal start and pressure on its Argentine customers, along with an ongoing legal dispute over a discontinued business. Agricultural input companies depend heavily on the planting calendar, so quarterly results often shift as sales move into later periods.

Segment Performance

Crop Protection revenue fell 12% to $29.1 million. Seed and Integrated Products revenue dropped 53% to $5.9 million, and Crop Nutrition revenue declined 20% to $18.8 million. The company said sales of soybean-related seed treatments started later in the quarter and partly shifted into the next reporting period.

Gross profit of $18.8 million fell 39%, and gross margin dropped 955 basis points to 35.0%. Lower sales volumes and an unfavorable product mix weighed on margins, while the company said selling, general and administrative costs remained broadly stable at $17.4 million despite inflationary pressure on its Argentine cost base.

Crop protection is the largest segment by revenue in the quarter, and its decline of 12% reflects the same timing and pricing pressure seen across the business. A competitive environment for adjuvants and specialty nutrition in Argentina added to the pressure.

Revenue decline in seed and integrated products was steeper, at 53%, because soybean-related seed treatments started later in the quarter.

Profitability and Adjusted EBITDA

Net loss from continuing operations was $10.8 million, compared with $4.7 million in the first quarter of the prior year. Adjusted EBITDA was $5.3 million, down from $13.9 million, although it improved sequentially for a second consecutive quarter.

The chief executive attributed the slow start to a slow beginning of the year, limited financial flexibility in some categories where customers needed longer-term financing, and greater price sensitivity among growers under cost pressure. The company said it is reiterating its Gross Profit and cost targets for the year.

Gross margin narrowed by 955 basis points, which is a large move in a single year. Lower volumes spread fixed costs across fewer sales, and a less favorable mix reduced the margin on each product sold.

Stable selling, general and administrative costs meant that the lower gross profit flowed directly into the widened net loss, showing how little room the cost base left to absorb the revenue decline.

The Pro Farm Group Dispute

In January 2026, the company's Pro Farm Group Business was subject to a foreclosure auction. Its assets, valued at $15.0 million, were awarded to an entity connected to a noteholder. For accounting purposes PFG has been classified as a discontinued operation, and the financial results discussed in the update exclude it.

Bioceres disputes the acceleration of the relevant notes and the foreclosure process. On October 21, 2026, the court allowed the company's claim under Article 9 of the New York Uniform Commercial Code and commercial reasonableness to proceed to discovery. The outcome of the case is not yet known.

The Pro Farm Group dispute involves a noteholder, a foreclosure process and questions about commercial reasonableness under New York law. Allowing the claim to proceed to discovery means the dispute will continue, and its outcome is not yet predictable.

Because PFG is classified as discontinued operations, its results are excluded from the continuing figures. The company's Balance Sheet and cash position, however, will be affected by any final resolution of the notes.

Outlook and Open Questions

The company's results depend heavily on the timing of seasonal sales in Argentina, which can move revenue between quarters. Management said some sales shifted into the next period, which means the first-quarter decline may partly reverse, but the update does not quantify how much.

Key questions for shareholders include whether the company can restore gross margin, how the discovery process affects its balance sheet and whether its financing constraints limit sales in the current season.

Financing constraints matter in this business because growers often buy inputs on credit. When financing is limited, farmers may buy less or choose lower-priced products, which affects the company's sales directly.

Final Word

Bioceres enters the fiscal year with lower revenue and margins, a larger loss from continuing operations and a legal dispute over a discontinued unit still moving through the courts. Sequential improvement in adjusted EBITDA is a positive signal, but the company's full-year targets depend on whether delayed seed treatment sales arrive in later quarters and whether customers can secure the financing they need. The second-quarter results and the discovery timeline will show whether the sales timing and legal issues move toward resolution.